
- 26. The fibrin adhesive granulate in accordance with claim 25, wherein the granulate pellets have a particle size in the range from approximately 100 μm to approximately 200 μm.
- 27. The fibrin adhesive granulate in accordance with claim 25, wherein said granulate pellets further comprise one or more substances chosen from albumin, fibronectin, or other substances that promote wound healing.
- 28. The fibrin adhesive granulate in accordance with claim 26, wherein said granulate pellets further comprise one or more substances chosen from albumin, fibronectin, or other substances that promote wound healing.
- 29. An effervescent preparation comprising a fibrin adhesive granulate as claimed in any one of claims 25 or 27 and substances required for the formation of CO<sub>2</sub>, wherein the effervescent preparation generates a foam suitable for hemostasis.
- 30. The effervescent preparation in accordance with claim 29, wherein the substances required for the formation of CO<sub>2</sub> comprise a mixture of a carbonate and a physiologically safe organic acid.
- 31. A wound care fleece comprising a biodegradable support medium, wherein the biodegradable support medium comprises a fibrin adhesive granulate as claimed in any one of claims 25 or 27.
- 32. The wound care fleece in accordance with claim 31, wherein the wound care fleece comprises a hydrophilic, non-aqueous salve base, and wherein said salve base comprises the fibrin adhesive.

LAW OFFICES
FINNECAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000



- 34. The wound care fleece in accordance with claim 31, wherein the biodegradable support medium comprises a polymer chosen from polyhydroxy carboxylic acids, polyesters, polycyano acrylates, polyamino acids, polyalcohols, or silicones.
- 35. The wound care fleece in accordance with claim 31, wherein said wound care fleece comprises fibrinogen in the range from approximately 0.05 mg/cm<sup>2</sup> to approximately 50 mg/cm<sup>2</sup> and thrombin in the range from approximately 1 μg/cm<sup>2</sup> to approximately 20 mg/cm<sup>2</sup>.
- 36. The wound care fleece in accordance with claim 31, wherein the preparation containing the fibrin adhesive is applied to one or both sides of the support medium.
- 37. A preparation comprising a fibrin adhesive as claimed in any one of claims 25 or 27.
- 38. The preparation in accordance with claim 37, wherein said preparation comprises a wound care fleece, and wherein said wound care fleece comprises a biodegradable support medium comprising the fibrin adhesive.
- 39. The preparation in accordance with claim 37, wherein said preparation comprises a bandage, wherein said bandage comprises a wound care fleece, and wherein said wound care fleece comprises a biodegradable support medium comprising the fibrin adhesive.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
8 DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

<u></u>

- 40. The preparation in accordance with claim 37 wherein said preparation comprises a plaster, wherein said plaster comprises a water proof or water permeable material, and wherein said material comprises a wound care fleece, and wherein said wound care fleece comprises a biodegradable support medium comprising the fibrin adhesive.
- 41. A preparation comprising a wound care fleece as claimed in claim 32.
- 42. A preparation comprising a hydrophilic, non-aqueous salve base, wherein said salve base comprises a fibrin adhesive as claimed in claim 25.
- 43. A method for the preparation of a fibrin adhesive granulate as claimed in claim 25 comprising,
  - suspending the components of the fibrin adhesive in an organic solvent, and spray-drying said suspension to a granulate of particle size in the range from approximately 50 µm to approximately 1000 µm.
- The method in accordance with claim 43, wherein the particle size of the granulate is in the range from approximately 100 μm to approximately 200 μm.
- 45. The method in accordance with claim 43, wherein the suspension is spray-dried onto a support medium.
- 46. The method in accordance with claim 44, wherein the suspension is spray-dried onto a support medium.
- A method for the preparation of a fibrin adhesive as claimed in claim 25, comprising
  - preparing a fibrinogen granulate, and

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

spraying an organic solvent comprising thrombin onto said fibrinogen granulate.

- 48. The method in accordance with claim 47, wherein a calcium salt is added to the fibrinogen granulate, to the thrombin solution, or to both the fibrinogen granulate and thrombin solution.
- 49. A method for the preparation of a fibrin adhesive granulate as claimed in claim25, comprising

preparing separate fibrinogen and thrombin granulates, and mixing the fibrinogen granulates with the thrombin granulates, wherein both types of granulates have a particle size in the range from approximately 50  $\mu$ m to approximately 1000  $\mu$ m.

- 50. A method for preparing a preparation comprising layering a fibrin adhesive granulate as claimed in claim 25 on a biodegradable support medium.
- 51. A method for preparing the preparation as claimed in claim 42 comprising mixing the fibrin adhesive with the hydrophilic, non-aqueous salve base.
- 52. A method for preparing a preparation comprising adding other biological, vegetable or synthetic active substances to the fibrin adhesive granulate as claimed in claim 25.
- 53. The method in accordance with claim 51, wherein biological, vegetable or synthetic active substances are chosen from immunoglobulins, chemotherapeutics or antibiotics.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000